TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Geometric mean fold rise (GMFR) of neutralization antibody titre in the medium dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: permanent skin flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of complete sports cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hypersensitivity (mid-term)
Endpoint domain: Adverse events/effects
Primary endpoint: Hypersensitivity (short-term)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive functional change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pediatric Balanced Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Berg Equilibrium Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Handicap Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Assessment Guide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean section prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Immunity complications in ITP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-calcified coronary plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in squame quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the sum of diameter product (SPD) of log10 conversion in target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the percentage of naive B cells to total B cells from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: early treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Broad mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived social support
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Completion of neoadjuvant therapy and surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in peak nasal inspiratory flow (PNIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with secondary intervention after EVAR
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement rate between triage outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant disease risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pink esthetic scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dental implant health scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hemi-diaphragmatic paresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Association between PRO and CROs over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: NLRC4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Spinal Cord Independence Measure (SCIM) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Geometric Mean Titer (GMT) of anti-RSV Subgroup A Neutralizing Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) of Anti-RSV/A Neutralizing Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in BOLD functional MRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in EEG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of blood at the 3rd and 4th stages of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Real Dollars Spent on Fruit and Vegetables Per Basket
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Social Wariness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social Preference
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline RASS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion enrolled in the CF Wellness Program (CFWP)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of cognitive behavioral therapy (CBT) sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of weeks participant synced the fitness tracker watch to the Smartphone app
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Requirement of Therapeutic Footwear change
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PSCI incidence
Endpoint domain: Mortality/survival
Primary endpoint: vadas-cog score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-month persistent opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: 3-month persistent post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pixel wise quantification of fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular itching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day of maximum probability of positive FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnosis of HCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of detection of a focal cerebral lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Treatment Evaluation Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fasting blood glucose level (FBG) in mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trunk imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tracheal stenosis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The Bristol Stool Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Assessment of Constipation Quality of Life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median size of ovarian follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Harris Hip Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Discontinuation of vasopressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of DAS28-CRP <=3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident Coronary Artery Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death Due to Cardiovascular Cause
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of deprescribing events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of complete molecular remissions (Mol-CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of medical late toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women with sporadic episodes of preterm uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of women with frequent and persistent episodes of preterm uterine contractions associated with pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of women needed for hospital admission for threatened preterm labour
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Parenting Stress Index- Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Attributions Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: View of entrance to larynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generation of artifactual data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Toronto Western Spasmodic Torticollis Rating Scale - Severity subscale (TWSTRS-Severity) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Tsui scale at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acceptability and feasibility of the outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Revised Nottingham Sensory Assessment (rNSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medical Research Council scale (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak oxygen consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Individual Signs and Symptoms of Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in blood CXCL9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients failing to initiate treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progress Free Survival 1 (PFS1)
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Last Specified Sampling Time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of ileal pouch/reservoir adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of osimertinib and minnelide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of minnelide and osimertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta (Y)AP sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta (X)ML sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average COP speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Traumatic Growth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental Cost-effectiveness ratio (ICER)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HPV eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St. George Respiratory Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Utility-weighted modified Rankin Scale (UW-mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aortic Cross-Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic Distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from severe to moderate or less mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptom scores and Palliative Referral Association
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall patients satisfaction with preoperative sedation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety of perioperative patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Radiation Dermatitis Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with respiratory distress complications requiring treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the severity of daily symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Regional brain uptake of [18F]P17-057
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative organ [18F]P17-059 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity concentration in blood and plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radioactivity concentration in urine and feces samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of metabolites and its proportion in plasma, urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver regional oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the ischemic burden (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the regional heart wall motion abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Abnormal foci of elevated bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood pooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Bone perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of DSMI and ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Electrofunctional evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to lentiviral gene therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events causally related to investigational surgical procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Arthritis Impact Measurement Scale 2-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TRE window clock time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Habitual eating window clock time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Image alignment in fetal MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracking quality in fetal MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 2 mile self-paced treadmill time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of the Sansa device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: nutritional complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cortical Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Step Length Asymmetry Adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Road Traffic Accidents
Endpoint domain: Mortality/survival
Primary endpoint: Measure of Pleural breakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score, resting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise or drop in blood pressure greater than or less than 150 bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of Cocaine HCl Topical Solution blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Cocaine HCl Topical Solution blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: congenital heart defect dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pressure gradient across valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life(QOL) (postpartum)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: New York Posture Assessment Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilizer Pressure Biofeedback
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontitis (presence/absence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of miricorilant (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero to the time of last measurable plasma concentration of miricorilant (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero extrapolated to infinity of plasma concentration of miricorilant (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SON-1010
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of IgE-antibodies to Alternaria species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Averaged cortisol response to stress and cannabis cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ratings of subjective craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of subjective stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metabolic cost of transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurocognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 2-year RFS rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in amount of gingival display
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Waist Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytokines concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pupil behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abnormalities in physical examination, vital signs, and clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal immune endotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in Investigator Global Assessment (IGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for MDZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for 1-OH-midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for MDZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for 1-OH-midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life questionnaire (QOLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in fibrosis due to NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Self-efficacy of children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in The L-dex (Lymphedema Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Image Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status